Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
- Conditions
- Malaria
- Registration Number
- NCT05155579
- Lead Sponsor
- University of Oxford
- Brief Summary
This is a Phase Ib trial conducted in Bougouni, Mali to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI vaccines in African children.
- Detailed Description
This trial has six groups. This will be a double-blind, individually randomised trial, with 1:1 randomisation with the single or two vial presentation of R21/Matrix-M malaria vaccine for study groups 1, 2 and 3. Groups 1, 2 and 3 are to assess the safety and immunogenicity of R21/Matrix-M as a single vial formulation compared with a two-vial formulation, in children aged 5- 36 months, in a malaria endemic area. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups.
For groups 4 and 5, this is a randomised, open-label study to assess the safety and immunogenicity of R21/Matrix-M when co-administrated with various EPI vaccines at the relevant ages, in a malaria endemic area.
Group 6 is a randomised, open-label study to assess safety and immunogenicity of a delayed, third dose of R21/Matrix-M in 5-36 month old children, in a malaria endemic area.
For groups 1, 2, 3, 5 and 6, participants will be randomised 1:1. For group 4, participants will be randomised 3:3:1.
Approximately 590 children will be recruited across these six study groups.
The primary study objectives are:
Safety
* To assess the safety and reactogenicity of R21/Matrix-M, as a single- vial formulation in 5-36-month old African children.
* To assess the safety and reactogenicity of co-administration of R21/Matrix-M with the EPI vaccines given at 9 months, measles-rubella and yellow fever vaccines, in African children.
* To assess the safety and reactogenicity of co-administration of R21/Matrix-M with the EPI vaccines given at 6, 10 and 14 weeks of age, pentavalent and oral polio vaccine (OPV), in African children.
Immunogenicity
* To assess the immunogenicity of R21/Matrix-M, as a single- vial formulation in 5-36-month-old African children, compared with the two-vial formulation.
* To assess the immunogenicity of EPI vaccines given at 9 months, measles-rubella and yellow fever vaccines, when given with and without R21/Matrix-M
* To assess the immunogenicity of EPI vaccines given at 6, 10 and 14 weeks of age, pentavalent and oral polio vaccines, given as part of EPI at 6, 10 and 14 weeks of age, when given with and without R21/Matrix-M.
The secondary study objectives are:
* To assess the safety and reactogenicity of R21/Matrix-M, as a single- vial formulation in African children compared with the two-vial formulation.
* To assess the safety and reactogenicity of a delayed third dose of R21/Matrix-M in 5-36-month-old African children.
* To assess the immunogenicity of a delayed third dose of R21/Matrix-M in 5-36-month-old African children.
This trial is funded by the Serum Institute of India.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 590
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety 2 years Solicited adverse events:
* Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination.
* Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.
Unsolicited adverse events
* Occurrence of unsolicited adverse events for 28 days following the vaccination. Laboratory adverse events
* Change from baseline for safety laboratory measures thought to be clinically significant.
Serious adverse events
• Occurrence of serious adverse events for the whole study duration.Immunogenicity 2 years * To assess the humoral immunogenicity of R21/Matrix-M as a single- vial formulation in 5-36-month-old African children, compared with the two-vial formulation, 0, 30, 180 and 365 days after the administration of the third dose of R21/Matrix-M; and 0, 30, 180 and 365 days after the administration of a booster dose.
* To assess the humoral immunogenicity of EPI vaccines given at 9 months, measles-rubella and yellow fever vaccines, when given with and without R21/Matrix-M, 0, 30, 180 and 360 days after the administration of the third dose of R21/Matrix-M
* To assess the humoral immunogenicity of EPI vaccines given at 6, 10 and 14 weeks of age, pentavalent and oral polio vaccines, given as part of EPI at 6, 10 and 14 weeks of age, when given with and without R21/Matrix-M, 0, 30, 180 and 360 days after the administration of the third dose of R21/Matrix-M or the EPI vaccines.
- Secondary Outcome Measures
Name Time Method Immunogenicity of a delayed third dose 2 years • To assess the humoral immunogenicity of a delayed third dose of R21/Matrix-M in 5-36-month-old African children, at 30 and 180 days after administration of the second dose, and 0, 30, 180 and 360 days after the administration of the third dose of R21/Matrix-M
Safety of a delayed third dose 2 years Solicited adverse events:
* Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination.
* Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination.
Unsolicited adverse events
* Occurrence of unsolicited adverse events for 28 days following the vaccination. Laboratory adverse events
* Change from baseline for safety laboratory measures thought to be clinically significant.
Serious adverse events
• Occurrence of serious adverse events for the whole study duration.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako
🇲🇱Bamako, Mali
CCVTM, University of Oxford
🇬🇧Oxford, United Kingdom
Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako🇲🇱Bamako, Mali